Table 3.
Statistical analyses and IC50 values of doxorubicin and doxorubicin plus N1-guanyl-1,7-diaminoheptane (GC7) treatment in eukaryotic translation initiation factor 5A2 (eIF5A2) siRNA-transfected bladder cancer cell lines
| Bladder cancer cell line | IC50 (μg/mL)† |
Two-way anova results |
||||
|---|---|---|---|---|---|---|
| Doxorubicin | Doxorubicin+GC7 | Treatment | Concentration | Interaction | ||
| F(1,60) | F(5,60) | F(5,60) | P-value | |||
| BIU-87 | 0.29 (0.25–0.32) | 0.20 (0.17–0.24) | 11.39** | 177.26*** | 2.20 | 0.074 |
| J82 | 0.29 (0.26–0.33) | 0.19 (0.17–0.21) | 24.79*** | 264.45*** | 1.96 | 0.107 |
| UM-UC-3 | 0.25 (0.21–0.28) | 0.20 (0.18–0.22) | 4.36* | 285.14*** | 1.43 | 0.231 |
*
P < 0.05;
**
P < 0.01;
***
P < 0.001.
†
IC50 value and 95% confidence interval of doxorubicin in each treatment.